Experience with long-term rituximab use in a multiple sclerosis clinic

BACKGROUND: Rituximab is a monoclonal antibody directed at CD20 positive B-lymphocytes and a potential therapeutic option in the treatment of multiple sclerosis. The safety of recurrent dosing is not established. OBJECTIVES: The objective of this work was to report the experience of long-term rituxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Barra, Megan E, Soni, Dhruv, Vo, Khac Huy, Chitnis, Tanuja, Stankiewicz, James M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433395/
https://www.ncbi.nlm.nih.gov/pubmed/28607739
http://dx.doi.org/10.1177/2055217316672100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433395/
https://www.ncbi.nlm.nih.gov/pubmed/28607739
http://dx.doi.org/10.1177/2055217316672100

Ejemplares similares